Real-world Effectiveness of Combination Therapies in Primary Care Asthma Management

• Status: Completed
• Trial end date: 2011-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate whether beclomethasone dipropionate / formoterol (BDP/FOR; Fostair® 100/6) is at least equivalent in terms of exacerbation prevention to fluticasone dipropionate / salmeterol (FP/SAL; Seretide® 125) in matched asthma patients switching to BDP/FOR following treatment with FP/SAL in normal clinical practice compared with patients not switched.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Research in Real-Life Ltd
• Collaborator: Chiesi Farmaceutici S.p.A.
• Treatments: Beclomethasone; Fluticasone; Fluticasone Propionate, Salmeterol Xinafoate Drug Combination; Formoterol Fumarate; Salmeterol Xinafoate

Criteria

Inclusion Criteria:

• Aged:

• 18-60 years:

• 61-80 years who are never-smokers

• Evidence of asthma:

• a diagnostic code for asthma, or

• ≥2 prescriptions for asthma at different points in time during the prior year

• Baseline FP/SAL therapy:

• ≥2 prescription for ICS/LABA therapy as FP/SAL (Seretide® 125).

Exclusion Criteria:

• Any chronic respiratory disease other than asthma

• Are receiving maintenance oral steroid therapy during baseline period.